Wells Fargo & Company Kazia Therapeutics LTD Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Kazia Therapeutics LTD stock. As of the latest transaction made, Wells Fargo & Company holds 500 shares of KZIA stock, worth $200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500Holding current value
$200% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding KZIA
# of Institutions
12Shares Held
323KCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY198KShares$79,1400.0% of portfolio
-
Hsbc Holdings PLC London, X064KShares$25,5820.0% of portfolio
-
Xtx Topco LTD London, X018.5KShares$7,3940.0% of portfolio
-
Two Sigma Securities, LLC New York, NY18.4KShares$7,3690.0% of portfolio
-
Rhumbline Advisers Boston, MA12.2KShares$4,8680.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $6.04M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...